Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Effects of soy isoflavones on cognitive function: a systematic review and meta-analysis of randomized controlled trials.

Cui C, Birru RL, Snitz BE, Ihara M, Kakuta C, Lopresti BJ, Aizenstein HJ, Lopez OL, Mathis CA, Miyamoto Y, Kuller LH, Sekikawa A.

Nutr Rev. 2019 Sep 4. pii: nuz050. doi: 10.1093/nutrit/nuz050. [Epub ahead of print]

PMID:
31504836
2.

[18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline.

Okonkwo DO, Puffer RC, Minhas DS, Beers SR, Edelman KL, Sharpless J, Laymon CM, Lopresti BJ, Benso S, Puccio AM, Pathak S, Ikonomovic MD, Mettenburg JM, Schneider W, Mathis CA, Mountz JM.

Front Neurol. 2019 Aug 2;10:831. doi: 10.3389/fneur.2019.00831. eCollection 2019.

3.

Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model.

Cardenes N, Aranda-Valderrama P, Carney JP, Sellares Torres J, Alvarez D, Kocydirim E, Wolfram Smith JA, Ting AE, Lagazzi L, Yu Z, Mason S, Santos E, Lopresti BJ, Rojas M.

BMJ Open Respir Res. 2019 Jan 12;6(1):e000308. doi: 10.1136/bmjresp-2018-000308. eCollection 2019.

4.

Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women.

Wu M, Thurston RC, Tudorascu DL, Karim HT, Mathis CA, Lopresti BJ, Kamboh MI, Cohen AD, Snitz BE, Klunk WE, Aizenstein HJ.

Neurobiol Aging. 2019 Apr;76:141-150. doi: 10.1016/j.neurobiolaging.2018.11.020. Epub 2018 Dec 1.

PMID:
30711677
5.

Longitudinal Evaluation of Pulmonary Arterial Hypertension in a Rhesus Macaque (Macaca mulatta) Model of HIV Infection.

Tarantelli RA, Schweitzer F, Simon MA, Vanderpool RR, Christman I, Rayens E, Kling HM, Zullo T, Carney JP, Lopresti BJ, Bertero T, Chan SY, Norris KA.

Comp Med. 2018 Dec 1;68(6):461-473. doi: 10.30802/AALAS-CM-18-000012. Epub 2018 Dec 12.

6.

Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Tudorascu DL, Anderson SJ, Minhas DS, Yu Z, Comer D, Lao P, Hartley S, Laymon CM, Snitz BE, Lopresti BJ, Johnson S, Price JC, Mathis CA, Aizenstein HJ, Klunk WE, Handen BL, Christian BT, Cohen AD.

Neurobiol Aging. 2019 Jan;73:171-176. doi: 10.1016/j.neurobiolaging.2018.09.030. Epub 2018 Sep 27.

PMID:
30359879
7.

Sleep moderates the relationship between amyloid beta and memory recall.

Wilckens KA, Tudorascu DL, Snitz BE, Price JC, Aizenstein HJ, Lopez OL, Erickson KI, Lopresti BJ, Laymon CM, Minhas D, Mathis CA, Buysse DJ, Klunk WE, Cohen AD.

Neurobiol Aging. 2018 Nov;71:142-148. doi: 10.1016/j.neurobiolaging.2018.07.011. Epub 2018 Jul 26.

8.

The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods.

Tudorascu DL, Minhas DS, Lao PJ, Betthauser TJ, Yu Z, Laymon CM, Lopresti BJ, Mathis CA, Klunk WE, Handen BL, Christian BT, Cohen AD.

Alzheimers Dement (Amst). 2018 Apr 21;10:332-339. doi: 10.1016/j.dadm.2018.03.006. eCollection 2018.

9.

Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, Tudorascu DL, Bulova PD, Lopresti BJ, Tumuluru RV, Murali D, Mathis CA, Barnhart TE, Stone CK, Price JC, Devenny DA, Johnson SC, Klunk WE, Christian BT.

J Alzheimers Dis. 2018;61(2):631-644. doi: 10.3233/JAD-170720.

10.

Small-molecule PET Tracers for Imaging Proteinopathies.

Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE.

Semin Nucl Med. 2017 Sep;47(5):553-575. doi: 10.1053/j.semnuclmed.2017.06.003. Epub 2017 Jul 13. Review.

11.

Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population.

Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, Tudorascu DL, Bulova PD, Lopresti BJ, Tumuluru RV, Murali D, Mathis CA, Barnhart TE, Stone CK, Price JC, Devenny DA, Mailick MR, Klunk WE, Johnson SC, Christian BT.

Alzheimers Dement (Amst). 2017 May 23;9:1-9. doi: 10.1016/j.dadm.2017.05.001. eCollection 2017.

12.

Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia.

Eisenmenger LB, Huo EJ, Hoffman JM, Minoshima S, Matesan MC, Lewis DH, Lopresti BJ, Mathis CA, Okonkwo DO, Mountz JM.

Semin Nucl Med. 2016 Jan;46(1):57-87. doi: 10.1053/j.semnuclmed.2015.09.003. Review.

PMID:
26687858
13.

Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.

Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, Klunk WE, Lopresti BJ, Mathis CA, Price JC.

J Nucl Med. 2015 Aug;56(8):1199-205. doi: 10.2967/jnumed.114.152405. Epub 2015 Jun 4.

14.

Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Narendran R, Jedema HP, Lopresti BJ, Mason NS, Himes ML, Bradberry CW.

Biol Psychiatry. 2015 Mar 1;77(5):488-92. doi: 10.1016/j.biopsych.2014.06.012. Epub 2014 Jun 23.

15.

Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28.

Narendran R, Lopresti BJ, Mason NS, Deuitch L, Paris J, Himes ML, Kodavali CV, Nimgaonkar VL.

J Neurosci. 2014 Jul 23;34(30):9945-50. doi: 10.1523/JNEUROSCI.0928-14.2014.

16.

In vivo imaging in an ABSL-3 regional biocontainment laboratory.

Scanga CA, Lopresti BJ, Tomko J, Frye LJ, Coleman TM, Fillmore D, Carney JP, Lin PL, Flynn JL, Gardner CL, Sun C, Klimstra WB, Ryman KD, Reed DS, Fisher DJ, Cole KS.

Pathog Dis. 2014 Jul;71(2):207-12. doi: 10.1111/2049-632X.12186. Epub 2014 Jun 18. Review.

PMID:
24838691
17.

Altered cerebellar and prefrontal cortex function in rhesus monkeys that previously self-administered cocaine.

Porter JN, Minhas D, Lopresti BJ, Price JC, Bradberry CW.

Psychopharmacology (Berl). 2014 Oct;231(21):4211-8. doi: 10.1007/s00213-014-3560-z. Epub 2014 Apr 15.

18.

Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis Chemotherapy Regimens.

Lin PL, Coleman T, Carney JP, Lopresti BJ, Tomko J, Fillmore D, Dartois V, Scanga C, Frye LJ, Janssen C, Klein E, Barry CE 3rd, Flynn JL.

Antimicrob Agents Chemother. 2013 Sep;57(9):4237-4244. doi: 10.1128/AAC.00277-13. Epub 2013 Jun 24.

19.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL.

Ann Neurol. 2013 Jun;73(6):751-61. doi: 10.1002/ana.23797. Epub 2013 Apr 17.

20.

Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study.

Narendran R, Jedema HP, Lopresti BJ, Mason NS, Gurnsey K, Ruszkiewicz J, Chen CM, Deuitch L, Frankle WG, Bradberry CW.

Mol Psychiatry. 2014 Mar;19(3):302-10. doi: 10.1038/mp.2013.9. Epub 2013 Feb 26. Erratum in: Mol Psychiatry. 2014 Mar;19(3):399.

21.

Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Mason NS, Lopresti BJ, Ruszkiewicz J, Dong X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR, Thomas SM.

Am J Nucl Med Mol Imaging. 2013;3(1):16-31. Epub 2013 Jan 5.

22.

Development of positron emission tomography β-amyloid plaque imaging agents.

Mathis CA, Mason NS, Lopresti BJ, Klunk WE.

Semin Nucl Med. 2012 Nov;42(6):423-32. doi: 10.1053/j.semnuclmed.2012.07.001. Review.

23.

Molecular imaging of microglia/macrophages in the brain.

Venneti S, Lopresti BJ, Wiley CA.

Glia. 2013 Jan;61(1):10-23. doi: 10.1002/glia.22357. Epub 2012 May 21. Review.

24.

In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA, Daley DC, Price JC, Mathis CA, Frankle WG.

Am J Psychiatry. 2012 Jan;169(1):55-63. doi: 10.1176/appi.ajp.2011.11010126. Epub 2011 Oct 31.

25.

Imaging of dopamine D2/3 agonist binding in cocaine dependence: a [11C]NPA positron emission tomography study.

Narendran R, Martinez D, Mason NS, Lopresti BJ, Himes ML, Chen CM, May MA, Price JC, Mathis CA, Frankle WG.

Synapse. 2011 Dec;65(12):1344-9. doi: 10.1002/syn.20970.

26.

Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ).

Laymon CM, Narendran R, Mason NS, Carney JP, Lopresti BJ, Mathis CA, Mountz JM, Sashin D, Frankle WG.

Mol Imaging Biol. 2012 Feb;14(1):115-22. doi: 10.1007/s11307-011-0478-2.

PMID:
21365327
27.

Influence of pediatric vaccines on amygdala growth and opioid ligand binding in rhesus macaque infants: A pilot study.

Hewitson L, Lopresti BJ, Stott C, Mason NS, Tomko J.

Acta Neurobiol Exp (Wars). 2010;70(2):147-64.

28.

A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum.

Narendran R, Mason NS, Laymon CM, Lopresti BJ, Velasquez ND, May MA, Kendro S, Martinez D, Mathis CA, Frankle WG.

J Pharmacol Exp Ther. 2010 May;333(2):533-9. doi: 10.1124/jpet.109.163501. Epub 2010 Jan 26.

29.

Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission.

Jedema HP, Gianaros PJ, Greer PJ, Kerr DD, Liu S, Higley JD, Suomi SJ, Olsen AS, Porter JN, Lopresti BJ, Hariri AR, Bradberry CW.

Mol Psychiatry. 2010 May;15(5):512-22, 446. doi: 10.1038/mp.2009.90. Epub 2009 Sep 1.

30.

2-18F-fluoroacetate: a useful tool for assessing gliosis in the central nervous system?

Lopresti BJ, Mason NS.

J Nucl Med. 2009 Jun;50(6):841-3. doi: 10.2967/jnumed.108.058875. Epub 2009 May 14. No abstract available.

31.

Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET.

Laymon CM, Mason NS, Frankle WG, Carney JP, Lopresti BJ, Litschge MY, Mathis CA, Mountz JM, Narendran R.

J Nucl Med. 2009 May;50(5):814-7. doi: 10.2967/jnumed.108.058131. Epub 2009 Apr 16.

32.

Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies.

Narendran R, Frankle WG, Mason NS, Laymon CM, Lopresti BJ, Price JC, Kendro S, Vora S, Litschge M, Mountz JM, Mathis CA.

Synapse. 2009 Jul;63(7):574-84. doi: 10.1002/syn.20633.

33.

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.

Arch Neurol. 2009 Jan;66(1):60-7. doi: 10.1001/archneurol.2008.511.

34.

Frequent amyloid deposition without significant cognitive impairment among the elderly.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE.

Arch Neurol. 2008 Nov;65(11):1509-17. doi: 10.1001/archneur.65.11.1509.

35.

Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.

Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE.

J Neurosci Methods. 2008 Jul 30;172(2):277-82. doi: 10.1016/j.jneumeth.2008.05.005. Epub 2008 May 16.

36.

Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B.

Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, Tsopelas ND, Lopresti BJ, Reynolds CF 3rd, DeKosky ST, Meltzer CC.

Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):261-8. doi: 10.1097/WAD.0b013e31816c92bf.

37.

Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration.

Venneti S, Bonneh-Barkay D, Lopresti BJ, Bissel SJ, Wang G, Mathis CA, Piatak M Jr, Lifson JD, Nyaundi JO, Murphey-Corb M, Wiley CA.

Am J Pathol. 2008 Jun;172(6):1603-16. doi: 10.2353/ajpath.2008.070967. Epub 2008 May 8.

38.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.

39.

Evaluation of a commercial radiochromatography module as an arterial blood activity monitor.

Laymon CM, Sashin D, Carney JP, Ruszkiewicz J, Altenburger D, Becker CR, Lopresti BJ, Mason NS, Mountz JM, Price JC, Schavey R, Mathis CA.

Phys Med Biol. 2008 Jan 21;53(2):339-51. doi: 10.1088/0031-9155/53/2/003. Epub 2007 Dec 28.

PMID:
18184990
40.

PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET.

Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, Apte UM, Wiley CA.

Neurobiol Aging. 2009 Aug;30(8):1217-26. doi: 10.1016/j.neurobiolaging.2007.11.005. Epub 2008 Feb 21.

41.

Impact of amyloid imaging on drug development in Alzheimer's disease.

Mathis CA, Lopresti BJ, Klunk WE.

Nucl Med Biol. 2007 Oct;34(7):809-22. Epub 2007 Sep 4. Review.

42.

The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: implications for PET imaging.

Venneti S, Wagner AK, Wang G, Slagel SL, Chen X, Lopresti BJ, Mathis CA, Wiley CA.

Exp Neurol. 2007 Sep;207(1):118-27. Epub 2007 Jun 19.

43.

A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation.

Venneti S, Lopresti BJ, Wang G, Slagel SL, Mason NS, Mathis CA, Fischer ML, Larsen NJ, Mortimer AD, Hastings TG, Smith AD, Zigmond MJ, Suhara T, Higuchi M, Wiley CA.

J Neurochem. 2007 Sep;102(6):2118-2131. doi: 10.1111/j.1471-4159.2007.04690.x. Epub 2007 Jun 7.

44.

Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST.

J Neurosci. 2007 Jun 6;27(23):6174-84.

45.

The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging.

Venneti S, Lopresti BJ, Wiley CA.

Prog Neurobiol. 2006 Dec;80(6):308-22. Epub 2006 Dec 6. Review.

46.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST.

Brain. 2006 Nov;129(Pt 11):2805-7. No abstract available.

PMID:
17071918
47.

Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment.

Wiley CA, Lopresti BJ, Becker JT, Boada F, Lopez OL, Mellors J, Meltzer CC, Wisniewski SR, Mathis CA.

J Neurovirol. 2006 Aug;12(4):262-71.

PMID:
16966217
48.

Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.

Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, DeKosky ST, Price JC.

Neuroimage. 2006 Oct 15;33(1):94-102. Epub 2006 Aug 14.

PMID:
16905334
49.

Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC.

J Nucl Med. 2005 Dec;46(12):1959-72.

50.

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.

J Neurosci. 2005 Nov 16;25(46):10598-606.

Supplemental Content

Loading ...
Support Center